SUNNYVALE, Calif., May 29, 2019 /PRNewswire/ -- Cepheid announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for testing throat and rectal specimens with its ...
> Invitae priced its IPO of 6,350,000 shares of common stock at an initial offering price of $16 per share, for total gross proceeds of $101.6 million. The company said it plans to trade on the NYSE ...
The FDA has cleared expanded claims for the Xpert Carba-R, a molecular test for the detection of carbapenemase-producing gram-negative bacteria, from Sunnyvale, Calif.-based Cepheid Inc. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results